Lv3
398 积分 2022-12-01 加入
Second primary malignancies in non-Hodgkin lymphoma: epidemiology and risk factors
6小时前
待确认
Secular trends in incidence and mortality of non-Hodgkin’s lymphoma in China, 1990–2019, and predictions to 2030: Outlook for the future burden of disease
6小时前
已完结
Development and validation of a prognostic nomogram for diffuse large B-cell lymphoma: a multicenter cohort study from Northern China
6小时前
已完结
Real-world outcomes with novel therapies in relapsed/refractory diffuse large B-cell lymphoma
6小时前
已完结
Primary diffuse large B-cell lymphoma in the era of targeted therapies: incidence, second primary malignancy and prognosis
7小时前
已完结
Glofitamab results in cost savings versus epcoritamab in relapsed/refractory diffuse large B-cell lymphoma: a total cost of care analysis ‡
7小时前
已完结
An Epidemiological Model to Estimate the Prevalence of Diffuse Large B-Cell Lymphoma in the United States
7小时前
求助中
Outcome of Relapsed or Refractory Diffuse Large B-cell Lymphoma with Second-line Chemotherapy Ifosfamide-Carboplatin-Etoposide with or without Rituximab
7小时前
求助中
Cost-effectiveness analysis of glofitamab versus rituximab for relapsed or refractory diffuse large B-cell lymphoma patients in China
7小时前
已完结
Unmet Needs in the First-Line Treatment of Diffuse Large B-cell Lymphoma: Expert Recommendations From the Asia-Pacific Region With a Focus on the Challenging Subtypes
7小时前
已完结
皖公网安备34019202002308
